Virotherapeutic treatment of cholangiocarcinoma using a novel armed oncolytic measles vaccine virus

Cholangiocarcinoma is curable only in early stages by complete surgical resection. Thus, in advanced disease stages in which a complete removal of the tumor mass is no longer possible and palliative chemotherapy only achieves modest success, therapeutics employing new methods of action are desperately needed. Oncolytic viruses employed in clinical studies have been shown to spread preferentially in cancer cells. Beyond that, virotherapeutic cell killing can be enhanced by virus-based expression of suicide genes. We engineered a measles vaccine virus (MeV) vector expressing SCD, a fusion protein of yeast cytosine…